Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083963 | 0.82 | ALDH1A1 (0.66) | ALDH1A1CYP3A4HPGDKMT2AL3MBTL1 | |
| SCHEMBL1945368 | 0.80 | ALDH1A1 (0.44) | ALDH1A1CYP3A4HPGDKMT2AL3MBTL1 | |
| SCHEMBL15766308 | 0.78 | GAA (0.76) | KMT2AGAAMEN1KDM4ETSHR | |
| SCHEMBL13928862 | 0.78 | MAPT (0.70) | ALDH1A1CYP3A4HPGDKMT2AL3MBTL1 | |
| SCHEMBL15558596 | 0.78 | ALDH1A1 (0.70) | ALDH1A1HPGDKMT2AL3MBTL1GAA | |
| SCHEMBL11622065 | 0.78 | MEN1 (0.56) | ALDH1A1CYP3A4HPGDKMT2AL3MBTL1 | |
| SCHEMBL1573850 | 0.78 | TSHR (0.50) | ALDH1A1HPGDKMT2AL3MBTL1GAA | |
| SCHEMBL13800067 | 0.76 | MAOA (0.44) | ALDH1A1CYP3A4HPGDKMT2AL3MBTL1 | |
| SCHEMBL31241378 | 0.75 | ATM (0.47) | ALDH1A1CYP3A4HPGDKMT2AL3MBTL1 | |
| SCHEMBL1945403 | 0.74 | ALDH1A1 (0.55) | ALDH1A1CYP3A4HPGDKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | MICROBA IP PTY LTD (AU) | 2026-01-29 | — | — | US | disclosed |
| US-9914703-B2 | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-20180016236-A1 | PYRIDIC KETONE DERIVATIVES, METHOD OF PREPARING SAME, AND PHARMACEUTICAL APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2018-01-18 | — | — | US | disclosed |
| EP-2445913-B1 | TRICYCLIC PYRIMIDINE DERIVATIVES AS WNT ANTAGONISTS | DEUTSCHES KREBSFORSCH (DE) | 2014-04-30 | — | — | EP | disclosed |
| US-8629272-B2 | Tricyclic pyrimidine derivatives as wnt antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629272-B2 | Tricyclic pyrimidine derivatives as wnt antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629272-B2 | Tricyclic pyrimidine derivatives as wnt antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120157481-A1 | TRICYCLIC PYRIMIDINE DERIVATIVES AS WNT ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM | 2012-06-21 | — | — | US | disclosed |
| WO-2004106337-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-6825349-B2 | PURINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS, IMMUNOLOGICAL DISORDERS, NEUROLOGICAL DISORDERS | CV THERAPEUTICS INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1444233-A2 | A 2B? ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1145716-B1 | Therapeutic agent for the treatment of dermatitis | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| US-6440978-B2 | A THERAPEUTICAL AGENT FOR DERMATITIS COMPRISES 7-AMINO-3-(HALO SUBSTITUTED OR UNSUBSTITUED BENZYL)-1,2,3-TETRAHYDRO-1-PHENYLPYRIDO(2,3-D)PYRIMIDIN-2,4-DIONE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-08-27 | — | — | US | disclosed |
| US-20010056097-A1 | Therapeutic agent for dermatitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-1145716-A2 | Therapeutic agent for the treatment of dermatitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 691/4885CYP3A4 1327/4885HPGD 899/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 691/4885CYP3A4 1327/4885HPGD 899/4885 |
| US-20010056097-A1 | Therapeutic agent for dermatitis | CCL11, TSLP, HRH4 | ALDH1A1 962/4885CYP3A4 3414/4885HPGD 269/4885 |
| US-20120157481-A1 | TRICYCLIC PYRIMIDINE DERIVATIVES AS WNT ANTAGONISTS | WNT1, WNT3, WNT3A | ALDH1A1 1200/4885CYP3A4 775/4885HPGD 1894/4885 |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 875/4885CYP3A4 1981/4885HPGD 718/4885 |
| US-20180016236-A1 | PYRIDIC KETONE DERIVATIVES, METHOD OF PREPARING SAME, AND PHARMACEUTICAL APPLICATION THEREOF | PDXK, MAP4K2, MAP3K6 | ALDH1A1 855/4885CYP3A4 279/4885HPGD 161/4885 |
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | VIP, SI, ALPI | ALDH1A1 3590/4885CYP3A4 2993/4885HPGD 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.